Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Myriad Genetics, Inc. - SIC # 2835 - IN VITRO AND IN VIVO DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
MYGN
Nasdaq
2835
https://myriad.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Myriad Genetics, Inc.
Myriad Genetics (MYGN) Wins Foundational Patent for MRD Assay
- Mar 27th, 2024 11:51 am
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
- Mar 22nd, 2024 1:40 am
Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device
- Mar 20th, 2024 8:05 pm
Myriad Genetics (MYGN) to Evaluate MRD Testing With New Pact
- Mar 1st, 2024 2:41 pm
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
- Feb 29th, 2024 2:50 pm
Myriad Genetics Full Year 2023 Earnings: EPS Misses Expectations
- Feb 29th, 2024 10:48 am
Q4 2023 Myriad Genetics Inc Earnings Call
- Feb 28th, 2024 4:24 pm
Myriad Genetics, Inc. (NASDAQ:MYGN) Q4 2023 Earnings Call Transcript
- Feb 28th, 2024 3:24 pm
Myriad Genetics (MYGN) Q4 Earnings Top Estimate, Margins Down
- Feb 28th, 2024 12:50 pm
Myriad (MYGN) Reports Q4 Earnings: What Key Metrics Have to Say
- Feb 28th, 2024 12:00 am
Myriad Genetics (MYGN) Tops Q4 Earnings and Revenue Estimates
- Feb 27th, 2024 11:30 pm
Myriad Genetics Inc (MYGN) Reports 11% Revenue Growth in Q4 and Full-Year 2023
- Feb 27th, 2024 9:42 pm
Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance
- Feb 27th, 2024 9:05 pm
Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3
- Feb 27th, 2024 2:15 pm
Wall Street's Insights Into Key Metrics Ahead of Myriad (MYGN) Q4 Earnings
- Feb 26th, 2024 2:16 pm
Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
- Feb 21st, 2024 9:05 pm
Larry Robbins' Glenview Capital Management Bolsters Stake in Myriad Genetics Inc
- Feb 16th, 2024 12:05 pm
Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health
- Feb 15th, 2024 9:05 pm
Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
- Feb 1st, 2024 2:25 pm
Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology
- Jan 30th, 2024 10:00 pm
Scroll